Detection of unknown primary tumours in patients with cerebral metastases using whole-body 18F-flouorodeoxyglucose positron emission tomography

European Journal of Neurology

Volumn 9, Issue 6, 2002, Pages 657-662

  Klee, B ^a   Law, I ^a   Hojgaard L ^a   Kosteljanetz, M ^a  

^a Rigshospitalet   (Denmark)

Author keywords

18 F fluorodeoxyglucose (18FDG); Brain metastasis; Unknown primary tumour; Whole body positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER TISSUE; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; FEMALE; HISTOLOGY; HUMAN; LUNG BIOPSY; LUNG TUMOR; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR; WHOLE BODY SCINTISCANNING; BRAIN TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METASTASIS; MIDDLE AGED; NEOPLASM; SCINTISCANNING; WHOLE BODY RADIATION;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY IRRADIATION;

EID: 0036835897     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2002.00467.x     Document Type: Article

References (28)

1. Bakheet SMB, Powe J, Ezzat A, Rostom A (1998). F-18-FDG uptake in tuberculosis. Clin Nucl Med 23:739-742.
2. Buchmann I, Reinhard M, Elsner K et al. (2001). 2-(Fluorine 18) fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91:889-899.
3. Chang P, Knapper WH (1982). Metastatic melanoma of unknown primary. Cancer 49:1106-1111.
4. Chee CP, Byrnes DP (1988). Cases of brain metastasis presenting as the first sign of systemic cancer. Singapore Med J 29:252-256.
5. Debevec M (1990). Management of patients with brain metastases of unknown origin. Neoplasma 37:601-606.
6. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE (1994). Performance characteristics of a whole-body PET scanner. J Nucl Med 35:1398-1406.
7. Eigtved A, Andersson AP, Dahlstrøm K et al. (2000). Use of fluorine -18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 27:70-75.
8. Fischer BMB, Mortensen J, Hojgaard L (2001). PET in the diagnosis and staging of lung cancer - A systematic, quantitative review of the litterature. Lancet Oncol 2:659-666.
9. Giuliano AE, Cochran AJ, Morton DL (1982). Melanoma from unknown primary site and anaelanotic melanoma. Seminars Oncol 9:442-447.
10. Goo JM, Im JG, Do KH et al. (2000). Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 216:117-121.
11. Gupta NC, Maloof J, Gunel E (1996). Probability of malignancy in solitary pulmonary nodules using fluorine 18-FDG and PET. J Nucl Med 37:943-948.
12. Gupta NC, Nicholson P, Bloomfield SM (1999). FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumours. Ann Surg 230:202-206.
13. Hatanaka M (1974). Transport of sugars in tumor cell membranes. Biochim Biophys Acta 355:77-104.
14. 18F] Fluoro-2-Deoxy-D-glucose. J Comput Assist Tomogr 17:582-589.
15. Kapucu LO, Meltzer CC, Townsend DW, Keenan RJ, Luketich JD (1998). F-18-fluorodeoxy-glucose up take in pneumonia. J Nucl Med 39:1267-1269.
16. 18F] FDG PET in management of metastatic brain tumours. Acta Neurochir 140:665-674.
17. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T (1992). Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972-1980.
18. Latief KH, White CS, Protopapas Z, Attar S, Krasna MJ (1997). Search for a primary lung neoplasm in patients with brain metastasis: is the chest radiograph sufficient? AJR Am J Roentgenol 168:1339-1344.
19. Le Chevalier T, Smith FP, Caille P, Constans JP, Rouesse JG (1985). Sites of primary malignancies in patients presenting with cerebral metastases. A review of 120 cases. Cancer 56:880-882.
20. Li P, Zhuang H, Mozley PD et al. (2001). Evaluation of recurrent squamous cell carcinoma of the head and neck with positron emission tomography. Clin Nucl Med 26:131-135.
21. Merchut MP (1989). Brain metastases from undiagnosed systemic neoplasm. Arch Intern Med 149:1076-1080.
22. Nussbaum ES, Djalilian HR, Cho KH, Hall WA (1996). Brain metastases: histology, multiplicity, surgery and survival. Cancer 78:1781-1788.
23. Perry A, Parisi JE, Kurtin PJ (1997). Metastatic adenocarcinoma to the brain: an immunohistochem approach. Hum Pathol 28:938-943.
24. van de Pol M, van Aalst VC, Wilmink TJ, Twijnstra A (1996). Brain metastases from unknown primary tumour: which diagnostic procedures are indicated? J Neurol Neurosurg Psychiatry 61:321-323.
25. Saleh FH, Crotty KA, Hersey P, Menzies SW (2001). Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int J Cancer 94:551-557.
26. Schlag P, Lehner B, Strauss LG, Georgi P, Herfarth C (1989). Scar or recurrent rectal cancer. Positron emission tomography is more helpful for diagnosis than immunoscintigraphy. Arch Surg 124:197-200.
27. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK (1996). Cost effectiveness of PET imaging in clinical oncology. Nucl Med Biol 23:737-743.
28. Weber G (1976). Enzymology of cancer cells. N EJM 296:541-551.